The global pharmaceutical company Roche is also developing ‘Trontinemab’ with a BBB ... These fibers are ma... K-Bio Control Tower aims to cultivate 110,000 specialists and 1 trillion won fund The ...

FS Investments, which had been considering moving its headquarters to the suburbs or another market entirely due to the ...

Brandywine Realty Trust, the dominant commercial landlord in Center City and the Main Line suburbs, last fall delayed plans for a life sciences-focused tower at ... at Roche’s Spark Therapeutics.

Over the past nine years, patients with spinal muscular atrophy have seen the number of FDA-approved treatment options for ...

Newleos Therapeutics is making its debut with $93.5 million aimed at developing safer and more effective neuroscience ...

Helmed by Roche alums, Newleos Therapeutics is taking over four drugs dropped from the Swiss pharma’s pipeline in early 2024.

Backed by Goldman Sachs, Novo Nordisk’s parent company and others, Newleos Therapeutics debuted Thursday with $94 million and ...

The primary driver behind last 12 months revenue was the Pharmaceuticals - Roche Pharmaceuticals segment contributing a total revenue of CHF46.3b (74% of total revenue). The largest operating ...

Earnings per share (EPS) missed analyst estimates by 38%. The primary driver behind last 12 months revenue was the Pharmaceuticals - Roche Pharmaceuticals segment contributing a total revenue of CHF46 ...